Recent News

• 02.12.2026 - BridgeBio Reports Positive Phase 3 Topline Results for Oral Infigratinib with the First Statistically Significant Improvements in Body Proportionality in Achondroplasia
• 01.27.2026 - CORRECTING and REPLACING -- BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 01.27.2026 - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
• 01.16.2026 - BridgeBio Prices Offering of $550 Million Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
• 01.14.2026 - BridgeBio Continues Long Term Debt Management Strategy and Announces Proposed Offering of Convertible Senior Notes due 2033 to Prefund Repayment of Convertible Senior Notes due 2027
• 01.12.2026 - BridgeBio Announces Commercial Progress, Program Updates, and 2026 Milestones at the 44th Annual J.P. Morgan Healthcare Conference
• 01.05.2026 - BridgeBio to Participate in the J.P. Morgan Healthcare Conference
• 01.02.2026 - BridgeBio to Host Achondroplasia Investor Webinar on Friday, January 9th at 8:00 am ET
• 12.22.2025 - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Recent Filings

• 02.12.2026 - 8-K Current report
• 02.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 02.12.2026 - EX-99.1 EX-99.1
• 01.21.2026 - EX-99.1 EX-99.1
• 01.21.2026 - 8-K Current report
• 01.12.2026 - 8-K Current report
• 01.12.2026 - 4 Statement of changes in beneficial ownership of securities
• 01.12.2026 - EX-99.1 EX-99.1
• 01.08.2026 - 144 Report of proposed sale of securities
• 01.08.2026 - 144 Report of proposed sale of securities